Lv4
640 积分 2021-08-14 加入
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
20小时前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
1个月前
已完结
The dormant cancer cell life cycle
3个月前
已完结
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
8个月前
已完结
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
9个月前
已完结
How can we integrate the biology of breast cancer cell dormancy into clinical practice?
9个月前
已完结
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
11个月前
已完结
Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer – Current Evidence and Future Directions
1年前
已完结
Distinct Recurrence Pattern and Survival Outcomes of Invasive Mucinous Adenocarcinoma of the Lung: The Potential Role of Local Therapy in Intrapulmonary Spread
1年前
已完结
Clinicopathologic Features and Survival Outcomes of Primary Lung Mucinous Adenocarcinoma Based on Different Radiologic Subtypes
1年前
已完结
皖公网安备34019202002308
